Performance Study Using the OptiScanner on Healthy Diabetics
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study is designed to demonstrate the accuracy of the OptiScanner glucose measurement. The accuracy of the test device will be determined using plasma samples collected directly from Type 1 and Type 2 Diabetics using the OptiScanner. Blood samples will simultaneously be collected and measured on YSI 2300 STAT PLUS (YSI) made by YSI Incorporated. These results will be compared to the OptiScanner's glucose measurement.
Condition or disease
Other: glucose and insulin IV to alter blood glucose
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Have signed an Informed Consent Form for this study approved by the Institutional Review Board (IRB)
Have a documented onset of diabetes ³ 1 year prior to this study
Have Type 1 or Type 2 diabetes according to the American Diabetes Association diagnostic criteria
Be currently treated with insulin (all regimens) for ³ 1 year and able (as judged by Investigator) and willing to undergo a hypoglycemic challenge and a hyperglycemic challenge; oral diabetes medication in combination with insulin is allowed
Be at least 18 but no more than 65 years of age
Be willing and able to comply with the requirements of the protocol
Be willing to refrain from participating in any other investigational study while enrolled in this study
For Female Subjects: Be post-menopausal, sterilized or not of child-bearing potential, or have a negative pregnancy test and have no intention of becoming pregnant between Visit 1 and Visit 2, and be using contraceptive devices or drugs (risk of pregnancy must be lower than 1%).
Recurrent major hypoglycemia (as judged by the Investigator) or hypoglycemia requiring hospitalization within the last 12 months
Have a history of hypoglycemic seizure within the last year
Impaired hepatic function measured as AST/ALT ³ two and a half times the upper reference limit or total bilirubin two and a half times the upper reference limit based on analysis from the local laboratory, or at the Investigator's discretion
Impaired renal function measured as creatinine ³ 1.5 (females) mg/dL, ³ 1.7 (males) mg/dL based on analysis from the local laboratory, or at the Investigator's discretion
Haematocrit or electrolytes (sodium, potassium) outside of normal limits based on analysis from the local laboratory, or at the investigator's discretion.
Have Uric Acid > 10 mg/dL based on analysis from the local laboratory
HIV positive, or Hepatitis B or C positive (blood test required). A viral load test will be done at the local laboratory for subjects with a positive Hepatitis result.
New York Heart Association (NYHA) Class III or IV congestive heart failure
Have a history of angina requiring hospitalization or a myocardial infarction within the last 12 months
Evidence of intermittent or sustained ventricular or supra-ventricular arrhythmias such as ventricular tachycardia, atrial fibrillation, etc. Holter monitoring may be performed to exclude arrhythmias at the discretion of the investigator.
Have active diabetic proliferative retinopathy (undergoing treatment)
Have active significant recurring skin infections or adhesive allergies, at the Investigator's discretion
Have given more than 150 mL of blood within 8 weeks prior to enrollment in this study
Currently taking anticoagulants, e.g. Coumadin (warfarin), Marcumar (phenprocoumon). Patients with prolonged activated PTT will not be included in this study.
Have received any investigational product or been treated with an invasive device within the past 30 days
Mental incapacity, unwillingness or language barrier precluding adequate understanding or co-operation
Any chronic illness that, in the judgment of the Investigator, may hinder or confuse compliance with the protocol
Any condition (may include clinically significant screening laboratory assessments) which, in the judgement of the Investigator, may increase the risk to the subject or decrease the likelihood of achieving the objectives of the study